Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2. ...
Tag: papillary renal cell carcinoma
#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...